

Blood Transfusion Considerations in High-Risk Pregnancies: Strategies and Outcomes

*Emmanuel Ifeanyi Obeagu¹ and Getrude Uzoma Obeagu²

¹Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda.

²School of Nursing Science, Kampala International University, Ishaka, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda.

Abstract

Blood transfusion management in high-risk pregnancies is a critical aspect of obstetric care aimed at mitigating maternal and fetal complications. This review examines the challenges, strategies, and outcomes associated with blood transfusions in pregnancies complicated by conditions such as antepartum hemorrhage, maternal medical disorders, and fetal anomalies. Challenges include the timely availability of blood products, managing coagulopathies, and balancing maternal and fetal risks. Strategies for optimizing transfusion practices encompass a multidisciplinary approach involving obstetricians, hematologists, and neonatologists, early recognition of complications, and the implementation of patient blood management principles. Advancements in transfusion technology, including point-of-care testing and cell salvage techniques, enhance the precision and safety of transfusions in high-risk scenarios. Improved outcomes include reduced maternal morbidity, enhanced fetal well-being, and optimized resource utilization. Future directions include further research into novel transfusion therapies and continued refinement of patient blood management protocols to address emerging challenges and improve care delivery.

Keywords: *blood transfusion, high-risk pregnancies, obstetrics, maternal-fetal medicine, strategies, outcomes*

Introduction

Pregnancy is a period of profound physiological changes that can pose significant challenges to maternal health, particularly in cases of high-risk pregnancies where complications such as antepartum hemorrhage, maternal medical disorders, and fetal anomalies necessitate specialized care. Blood transfusion emerges as a critical intervention in obstetric practice, serving to stabilize maternal hemodynamics, correct maternal anemia, and address fetal hematological abnormalities. The management of blood transfusions in these complex scenarios requires careful consideration of maternal-fetal physiology, logistical constraints, and ethical considerations to optimize outcomes for both mother and baby.¹⁻⁵ High-risk pregnancies are characterized by conditions that

Citation: Obeagu EI, Obeagu GU. Blood Transfusion Considerations in High-Risk Pregnancies: Strategies and Outcomes. Elite Journal of Medical Sciences, 2024; 2(5):40-50

increase the likelihood of maternal and fetal morbidity and mortality, challenging healthcare providers to balance aggressive management with careful risk assessment. Antepartum hemorrhage, including placental abruption and uterine rupture, can result in rapid maternal blood loss necessitating urgent transfusion to maintain maternal perfusion and prevent maternal collapse. The management of maternal medical disorders such as severe anemia, thrombocytopenia, and coagulopathies further complicates transfusion decisions, requiring tailored approaches to mitigate risks while addressing underlying pathologies.⁶⁻¹⁰ Fetal conditions such as Rh alloimmunization, intrauterine growth restriction (IUGR), and congenital anomalies may necessitate specialized fetal transfusion interventions to optimize fetal outcomes. These procedures, guided by advanced imaging and performed in collaboration with maternal-fetal medicine specialists and transfusion medicine teams, highlight the evolving complexity and interdisciplinary nature of modern obstetric care. The ethical considerations surrounding transfusion in pregnancy, including informed consent and the management of potential transfusion-related risks such as alloimmunization and infections, underscore the importance of patient-centered care and shared decision-making between healthcare providers and patients.¹¹⁻¹⁵

The optimization of blood transfusion practices in high-risk pregnancies requires a multidisciplinary approach involving obstetricians, hematologists, anesthesiologists, neonatologists, and transfusion specialists. This collaborative effort aims to anticipate and mitigate complications through comprehensive prenatal monitoring, early recognition of risk factors, and timely intervention. Patient blood management (PBM) principles, including preoperative optimization of maternal hemoglobin levels, minimization of blood loss during delivery through controlled cord traction techniques, and judicious use of blood products, are integral to reducing the need for allogeneic transfusions and improving maternal outcomes.¹⁶⁻²⁰ Technological advancements in transfusion medicine have revolutionized the management of blood transfusions in obstetrics, offering tools such as point-of-care testing for rapid blood typing and cross-matching, which facilitate timely transfusion decisions in critical situations. Intraoperative cell salvage techniques allow for the recovery and reinfusion of maternal blood lost during cesarean sections, minimizing the exposure to allogeneic blood products and associated risks. These innovations contribute to safer transfusion practices and improved maternal-fetal outcomes by addressing the unique challenges posed by high-risk pregnancies.²¹⁻²⁵ Despite these advancements, challenges persist in the logistical aspects of transfusion management, including the timely availability and storage of blood products, particularly in resource-constrained settings or during emergencies. The global disparities in access to safe blood products underscore the need for sustainable strategies to ensure equitable healthcare delivery and optimize maternal-fetal outcomes worldwide. Furthermore, ongoing research into novel transfusion therapies, including the development of artificial blood substitutes and targeted therapies for specific maternal and fetal conditions, holds promise for further enhancing transfusion safety and efficacy in high-risk pregnancies.²⁶⁻³⁰

Challenges in Blood Transfusion for High-Risk Pregnancies

High-risk pregnancies present unique challenges in the management of blood transfusions, necessitating specialized approaches to ensure maternal and fetal well-being. These challenges stem from the complex interplay of maternal medical conditions, fetal anomalies, and the

Citation: Obeagu EI, Obeagu GU. Blood Transfusion Considerations in High-Risk Pregnancies: Strategies and Outcomes. Elite Journal of Medical Sciences, 2024; 2(5):40-50

physiological changes inherent to pregnancy.³¹ One of the primary challenges in high-risk pregnancies is the management of antepartum hemorrhage, which can occur due to conditions such as placental abruption, uterine rupture, or placenta previa. These emergencies often require rapid and substantial transfusion of blood products to stabilize maternal hemodynamics and prevent maternal shock. Timing and appropriateness of transfusion interventions are critical, as delays can significantly impact maternal survival and fetal outcomes.³²⁻³⁵ Maternal medical conditions pose another significant challenge in transfusion management during pregnancy. Conditions such as severe anemia, thrombocytopenia, and coagulopathies complicate the transfusion decision-making process. Balancing the need to correct maternal hematologic abnormalities with the potential risks to both mother and fetus requires careful consideration of transfusion thresholds, alternative therapies, and monitoring for transfusion-related complications.³⁶⁻³⁸

Fetal conditions also influence transfusion challenges in high-risk pregnancies. For instance, Rh alloimmunization and fetal anemia may necessitate specialized fetal transfusion procedures, such as intrauterine transfusion (IUT), to prevent hydrops fetalis and optimize fetal growth and development. Coordinating these procedures with maternal-fetal medicine specialists and transfusion teams is essential to ensure timely and safe interventions.³⁹⁻⁴⁰ Logistical challenges add another layer of complexity to transfusion management in high-risk pregnancies. Ensuring the timely availability of compatible blood products, particularly in emergencies or in regions with limited resources, can be challenging. Moreover, the storage and transportation of blood products under optimal conditions are crucial to maintaining their efficacy and safety, highlighting the need for robust logistical support and infrastructure.⁴¹⁻⁴² Ethical considerations also play a significant role in transfusion decisions during pregnancy. Informed consent, respecting patient autonomy, and managing potential transfusion-related risks such as alloimmunization and infections are essential aspects of ethical practice in obstetric transfusion medicine. Healthcare providers must navigate these ethical dilemmas while striving to provide the best possible care for both mother and fetus.⁴³⁻⁴⁴ Lastly, disparities in access to healthcare resources globally amplify the challenges of transfusion management in high-risk pregnancies. Variations in healthcare infrastructure, availability of blood products, and access to specialized transfusion services can impact clinical outcomes and necessitate innovative approaches to optimize care delivery in diverse settings.⁴⁵⁻⁴⁶

Strategies for Optimizing Blood Transfusion in High-Risk Pregnancies

Optimizing blood transfusion practices in high-risk pregnancies is essential to mitigate maternal and fetal complications effectively. Several strategies are employed to enhance safety, improve outcomes, and ensure appropriate utilization of blood products in these complex clinical scenarios. These strategies encompass multidisciplinary collaboration, evidence-based protocols, and advancements in transfusion technology tailored to the specific needs of pregnant patients facing medical complexities.⁴⁷⁻⁵⁰ A fundamental strategy is the establishment of multidisciplinary teams comprising obstetricians, hematologists, anesthesiologists, neonatologists, and transfusion specialists. This collaborative approach facilitates comprehensive assessment and management of maternal conditions that may necessitate transfusion, such as antepartum hemorrhage or severe anemia. Regular communication and joint decision-making ensure timely interventions and continuity of care, optimizing maternal and fetal outcomes.⁵¹⁻⁵² Early recognition and proactive

Citation: Obeagu EI, Obeagu GU. Blood Transfusion Considerations in High-Risk Pregnancies: Strategies and Outcomes. Elite Journal of Medical Sciences, 2024; 2(5):40-50

management of risk factors play a crucial role in optimizing transfusion practices. Antenatal monitoring and assessment allow healthcare providers to identify conditions predisposing to hemorrhage or hematologic disorders promptly. This early detection enables timely implementation of preventive measures and, when necessary, early initiation of transfusion therapy to preempt worsening maternal or fetal conditions.⁵³⁻⁵⁴

Patient blood management (PBM) principles are integral to reducing the need for allogeneic transfusions and enhancing transfusion safety in high-risk pregnancies. PBM strategies include preoperative optimization of maternal hemoglobin levels through iron supplementation or erythropoietin therapy, minimizing blood loss during delivery with meticulous surgical techniques, and judicious use of blood products based on individualized transfusion triggers. These strategies not only conserve blood resources but also mitigate transfusion-related risks, such as infections and immunologic reactions.⁵⁵⁻⁵⁶ Advancements in transfusion technology contribute significantly to optimizing blood transfusions in high-risk pregnancies. Point-of-care testing for rapid blood typing and cross-matching facilitates timely transfusion decisions, particularly in emergent situations. Intraoperative cell salvage systems recover and reinfuse maternal blood lost during cesarean sections, reducing the need for allogeneic transfusions and enhancing maternal safety. These technological innovations improve transfusion efficacy and patient outcomes by minimizing delays and optimizing resource utilization.⁵⁷⁻⁵⁸ Specialized fetal transfusion procedures, such as intrauterine transfusion (IUT), are employed in cases of severe fetal anemia or Rh alloimmunization to optimize fetal health. These procedures are guided by advanced imaging techniques and performed in collaboration with maternal-fetal medicine specialists and transfusion teams, ensuring precise and safe interventions tailored to fetal requirements.⁵⁹⁻⁶⁰ Ethical considerations in transfusion management remain paramount in high-risk pregnancies. Informed consent, respecting patient autonomy, and transparent communication regarding potential risks and benefits of transfusion interventions are essential aspects of ethical practice. Healthcare providers must engage patients in shared decision-making, taking into account individual preferences and values while ensuring optimal maternal and fetal outcomes.⁶¹⁻⁶²

Outcomes

Optimizing blood transfusion practices in high-risk pregnancies yields significant positive outcomes for both maternal and fetal health. Timely and appropriate transfusion interventions help stabilize maternal hemodynamics, correct maternal hematologic abnormalities such as severe anemia or coagulopathies, and mitigate risks associated with antepartum hemorrhage. By addressing these critical factors promptly, healthcare providers can reduce maternal morbidity and mortality rates, improving overall maternal health outcomes.⁶³⁻⁶⁴ Fetal outcomes are also positively impacted by optimized transfusion practices in high-risk pregnancies. Specialized fetal transfusion procedures, such as intrauterine transfusion (IUT) for severe fetal anemia or Rh alloimmunization, contribute to reducing the incidence of fetal complications such as hydrops fetalis and intrauterine growth restriction (IUGR). These interventions are guided by advanced imaging techniques and performed by skilled maternal-fetal medicine specialists in collaboration with transfusion teams, ensuring precise and effective management of fetal hematologic conditions.⁶⁵⁻⁶⁶ Furthermore, adherence to patient blood management (PBM) principles reduces the reliance on allogeneic blood

Citation: Obeagu EI, Obeagu GU. Blood Transfusion Considerations in High-Risk Pregnancies: Strategies and Outcomes. Elite Journal of Medical Sciences, 2024; 2(5):40-50

products, thereby minimizing transfusion-related risks such as infections, immunologic reactions, and transfusion-associated circulatory overload (TACO). By optimizing resource utilization and enhancing transfusion safety, PBM strategies contribute to improved clinical outcomes and patient satisfaction in high-risk pregnancies.⁶⁷⁻⁶⁸

Future Directions

Continued advancements in point-of-care testing technologies for rapid blood typing and cross-matching will facilitate even faster and more accurate transfusion decisions in emergency settings, improving response times and patient outcomes. Additionally, the development of artificial blood substitutes and novel transfusion therapies tailored to specific maternal and fetal conditions holds potential for reducing the dependency on donor blood products and mitigating associated risks.⁶⁹⁻

⁷⁰ Integration of artificial intelligence (AI) and machine learning algorithms into transfusion management protocols may further optimize transfusion strategies by predicting patient-specific transfusion needs based on clinical data and outcomes. These technologies could enhance decision support systems for healthcare providers, ensuring personalized and precise transfusion interventions tailored to individual patient profiles and medical histories.⁷¹⁻⁷² Furthermore, global initiatives to improve access to safe blood products and transfusion services are crucial for addressing disparities in healthcare delivery and optimizing outcomes in high-risk pregnancies worldwide. Collaborative efforts among healthcare organizations, policymakers, and community stakeholders are essential to implementing sustainable transfusion practices and enhancing healthcare infrastructure in resource-limited settings.⁷³

Conclusion

Optimizing blood transfusion practices in high-risk pregnancies represents a critical component of modern obstetric care aimed at improving maternal and fetal outcomes. By implementing multidisciplinary teams comprising obstetricians, hematologists, anesthesiologists, and maternal-fetal medicine specialists, healthcare providers can ensure comprehensive and timely management of transfusion needs in high-risk pregnancies. Early recognition of risk factors, proactive monitoring, and adherence to patient blood management principles play pivotal roles in reducing the need for allogeneic transfusions and optimizing maternal health outcomes. Technological innovations such as point-of-care testing and intraoperative cell salvage systems have revolutionized transfusion practices, enabling faster decision-making and minimizing delays in critical situations. These advancements contribute to safer transfusion interventions and improve resource utilization, addressing logistical challenges and enhancing healthcare delivery for pregnant patients worldwide.

References

1. Smith C, Teng F, Branch E, Chu S, Joseph KS. Maternal and perinatal morbidity and mortality associated with anemia in pregnancy. *Obstetrics & Gynecology*. 2019;134(6):1234-1244.

Citation: Obeagu EI, Obeagu GU. Blood Transfusion Considerations in High-Risk Pregnancies: Strategies and Outcomes. *Elite Journal of Medical Sciences*, 2024; 2(5):40-50

2. Shi H, Chen L, Wang Y, Sun M, Guo Y, Ma S, Wang X, Jiang H, Wang X, Lu J, Ge L. Severity of anemia during pregnancy and adverse maternal and fetal outcomes. JAMA network open. 2022;5(2):e2147046-.
3. Harrison RK, Lauhon SR, Colvin ZA, McIntosh JJ. Maternal anemia and severe maternal morbidity in a US cohort. American journal of obstetrics & gynecology MFM. 2021;3(5):100395.
4. Beckert RH, Baer RJ, Anderson JG, Jelliffe-Pawlowski LL, Rogers EE. Maternal anemia and pregnancy outcomes: a population-based study. Journal of Perinatology. 2019;39(7):911-919.
5. Daru J, Zamora J, Fernández-Félix BM, Vogel J, Oladapo OT, Morisaki N, Tunçalp Ö, Torloni MR, Mittal S, Jayaratne K, Lumbiganon P. Risk of maternal mortality in women with severe anaemia during pregnancy and post partum: a multilevel analysis. The Lancet Global Health. 2018;6(5):e548-554.
6. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC, Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria, J Res Med Dent Sci, 2021, 9 (4):145-148
7. Obeagu EI, Agreeen FC. Anaemia among pregnant women: A review of African pregnant teenagers. J Pub Health Nutri. 2023; 6 (1). 2023;138. [links/63da799664fc860638054562/Anaemia-among-pregnant-women-A-review-of-African-pregnant-teenagers.pdf](https://doi.org/10.3390/10.3390/63da799664fc860638054562/Anaemia-among-pregnant-women-A-review-of-African-pregnant-teenagers.pdf).
8. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 2016;3(3):10-8. [links/5710fae108ae846f4ef05afb/ERYTHROPOIETIN-IN-THE-ANAEMIAS-OF-PREGNANCY-A-REVIEW.pdf](https://doi.org/10.3390/10.3390/5710fae108ae846f4ef05afb/ERYTHROPOIETIN-IN-THE-ANAEMIAS-OF-PREGNANCY-A-REVIEW.pdf).
9. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC. Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria. J Res Med Dent Sci. 2021;9(4):145-8. [links/608a6728a6fdccaebdf52d94/Assessment-of-Haematological-Changes-in-Pregnant-Women-of-Ido-Ondo.pdf](https://doi.org/10.3390/10.3390/608a6728a6fdccaebdf52d94/Assessment-of-Haematological-Changes-in-Pregnant-Women-of-Ido-Ondo.pdf).
10. Obeagu EI, Obeagu GU. Sick Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 ;6(2):10-3. <http://irmhs.com/index.php/irmhs/article/view/111>.
11. Georgieff MK. Iron deficiency in pregnancy. American journal of obstetrics and gynecology. 2020;223(4):516-524.
12. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. Evaluation of Protein C, Protein S and Fibrinogen of Pregnant Women with Malaria in Owerri Metropolis. Madonna University journal of Medicine and Health Sciences. 2022;2(2):1-9.
13. Obeagu EI, Ikpenwa JN, Chukwueze CM, Obeagu GU. Evaluation of protein C, protein S and fibrinogen of pregnant women in Owerri Metropolis. Madonna University Journal of Medicine and Health Sciences. 2022;2(1):292-8. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/57>.
14. Obeagu EI, Obeagu GU, Adepoju OJ. Evaluation of haematological parameters of pregnant women based on age groups in Olorunsogo road area of Ido, Ondo state. J. Bio. Innov11 (3). 2022:936-941.

Citation: Obeagu EI, Obeagu GU. Blood Transfusion Considerations in High-Risk Pregnancies: Strategies and Outcomes. Elite Journal of Medical Sciences, 2024; 2(5):40-50

15. Cantor AG, Bougatsos C, Dana T, Blazina I, McDonagh M. Routine iron supplementation and screening for iron deficiency anemia in pregnancy: a systematic review for the US Preventive Services Task Force. *Annals of internal medicine*. 2015;162(8):566-576.
16. Siu AL, US Preventive Services Task Force*. Screening for iron deficiency anemia and iron supplementation in pregnant women to improve maternal health and birth outcomes: US Preventive Services Task Force recommendation statement. *Annals of Internal Medicine*. 2015;163(7):529-536.
17. Obeagu EI. An update on utilization of antenatal care among pregnant Women in Nigeria. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2022;9(9): 21-6.DOI: [10.22192/ijcreps.2022.09.09.003](https://doi.org/10.22192/ijcreps.2022.09.09.003)
18. Okoroiwu IL, Obeagu EI, Obeagu GU. Determination of clot retraction in pregnant women attending antenatal clinic in federal medical centre Owerri, Nigeria. *Madonna University Journal of Medicine and Health Sciences*. 2022;2(2):91-97. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/67>.
19. Obeagu EI, Hassan AO, Adepoju OJ, Obeagu GU, Okafor CJ. Evaluation of Changes in Haematological Parameters of Pregnant Women Based on Gestational Age at Olorunsogo Road Area of Ido, Ondo State. Nigeria. *Journal of Research in Medical and Dental Science*. 2021;9(12):462-.[links/61b1e32f0c4bfb675178bfa7/Evaluation-of-Changes-in-Haematological-Parameters-of-Pregnant-Women-Based-on-Gestational-Age-at-Olorunsogo-Road-Area-of-Ido-Ondo-State-Nigeria.pdf](https://www.researchinmedicalanddentalscience.com/links/61b1e32f0c4bfb675178bfa7/Evaluation-of-Changes-in-Haematological-Parameters-of-Pregnant-Women-Based-on-Gestational-Age-at-Olorunsogo-Road-Area-of-Ido-Ondo-State-Nigeria.pdf).
20. Anyiam AF, Obeagu EI, Obi E, Omosigho PO, Ironi EA, Arinze-Anyiam OC, Asiyah MK. ABO blood groups and gestational diabetes among pregnant women attending University of Ilorin Teaching Hospital, Kwara State, Nigeria. *International Journal of Research and Reports in Hematology*. 2022 Jun 21;5(2):113-121.
21. Obeagu EI. Gestational Thrombocytopaenia. *J Gynecol Women's Health*. 2023;25(3):556163. [links/64b01aa88de7ed28ba95fccb/Gestational-Thrombocytopaenia.pdf](https://www.researchinmedicalanddentalscience.com/links/64b01aa88de7ed28ba95fccb/Gestational-Thrombocytopaenia.pdf).
22. Liu CN, Yu FB, Xu YZ, Li JS, Guan ZH, Sun MN, Liu CA, He F, Chen DJ. Prevalence and risk factors of severe postpartum hemorrhage: a retrospective cohort study. *BMC pregnancy and childbirth*. 2021;21(1):332.
23. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-9.
24. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU. Obstetrics characteristics that effect the newborn outcomes. *Int. J. Adv. Res. Biol. Sci.* 2023;10(3): 134-43.DOI: [10.22192/ijarbs.2023.10.03.016](https://doi.org/10.22192/ijarbs.2023.10.03.016)
25. Obeagu EI, Ogunnaya FU. PREGNANCYINDUCED HAEMATOLOGICAL CHANGES: A KEY TO MATERNAL AND CHILD HEALTH. *European Journal of Biomedical*. 2023;10(8):42-43. [links/64c890bddb38b20d6dad2c5c/PREGNANCY-INDUCED-HAEMATOLOGICAL-CHANGES-A-KEY-TO-MATERNAL-AND-CHILD-HEALTH.pdf](https://www.researchinmedicalanddentalscience.com/links/64c890bddb38b20d6dad2c5c/PREGNANCY-INDUCED-HAEMATOLOGICAL-CHANGES-A-KEY-TO-MATERNAL-AND-CHILD-HEALTH.pdf).
26. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.

Citation: Obeagu EI, Obeagu GU. Blood Transfusion Considerations in High-Risk Pregnancies: Strategies and Outcomes. *Elite Journal of Medical Sciences*, 2024; 2(5):40-50

27. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. *Annals of Clinical and Laboratory Research*. 2017;5(4):206. [links/5ea97df145851592d6a8acf2/Iron-Status-of-Pregnant-and-Post-Partum-Women-with-Malaria-Parasitaemia-in-Aba-Abia-State-Nigeria.pdf](https://epjournals.com/links/5ea97df145851592d6a8acf2/Iron-Status-of-Pregnant-and-Post-Partum-Women-with-Malaria-Parasitaemia-in-Aba-Abia-State-Nigeria.pdf).
28. Eze RI, Obeagu EI, Edet FN. Frequency of Rh Antigen C And c among pregnant women in Sub-Urban area in Eastern Nigeria. *Madonna Uni J Med Health Sci*. 2021;1(1):19-30.
29. Obeagu EI, Ofodile AC, Okwuanaso CB. A review of urinary tract infections in pregnant women: Risks factors. *J Pub Health Nutri*. 2023; 6 (1). 2023; 137:26-35. [links/63c3a9116fe15d6a571e8bba/A-review-of-urinary-tract-infections-in-pregnant-women-Risks-factors.pdf](https://epjournals.com/links/63c3a9116fe15d6a571e8bba/A-review-of-urinary-tract-infections-in-pregnant-women-Risks-factors.pdf).
30. Obeagu EI, Obeagu GU, Musiimenta E. Post partum haemorrhage among pregnant women: Update on risks factors. *Int. J. Curr. Res. Med. Sci*. 2023;9(2): 14-17.DOI: [10.22192/ijcrms.2023.09.02.003](https://doi.org/10.22192/ijcrms.2023.09.02.003)
31. Obeagu EI, Obeagu GU, Ogunnaya FU. Deep vein thrombosis in pregnancy: A review of prevalence and risk factors. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2023;10(8): 14-21.DOI: [10.22192/ijcrps.2023.10.08.002](https://doi.org/10.22192/ijcrps.2023.10.08.002)
32. Pacheco LD, Saade GR, Costantine MM, Clark SL, Hankins GD. An update on the use of massive transfusion protocols in obstetrics. *American journal of obstetrics and gynecology*. 2016;214(3):340-344.
33. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of some haematological parameters in malaria infected pregnant women in Imo state Nigeria. *Int. J. Curr. Res. Biol. Med*. 2018;3(9): 1-4.DOI: [10.22192/ijcrbm.2018.03.09.001](https://doi.org/10.22192/ijcrbm.2018.03.09.001)
34. Onyenweaku FC, Amah HC, Obeagu EI, Nwandikor UU, Onwuasoanya UF. Prevalence of asymptomatic bacteriuria and its antibiotic susceptibility pattern in pregnant women attending private ante natal clinics in Umuahia Metropolitan. *Int J Curr Res Biol Med*. 2017;2(2): 13-23.DOI: [10.22192/ijcrbm.2017.02.02.003](https://doi.org/10.22192/ijcrbm.2017.02.02.003)
35. Okoroiwu IL, Chinedu-Madu JU, Obeagu EI, Vincent CC, Ochiabuto OM, Ibekwe AM, Amaechi CO, Agu CC, Anoh NV, Amadi NM. Evaluation of Iron Status, Haemoglobin and Protein Levels of Pregnant Women in Owerri Metropolis. *Journal of Pharmaceutical Research International*. 2021;33(27A):36-43.
36. Obeagu EI, Njar VE, Obeagu GU. Infertility: Prevalence and Consequences. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2023;10(7):43-50.
37. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Evaluation of levels of some inflammatory cytokines in preeclamptic women in owerri. *Journal of Pharmaceutical Research International*. 2021;33(42A):53-65.
38. Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, Gernsheimer T, Holcomb JB, Kaplan LJ, Katz LM, Peterson N. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. *Jama*. 2016;316(19):2025-2035.
39. Obeagu EI, Faduma MH, Uzoma G. Ectopic Pregnancy: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2023;10(4): 40-4.DOI: [10.22192/ijcrps.2023.10.04.004](https://doi.org/10.22192/ijcrps.2023.10.04.004)
40. Obeagu EI, Gamade SM, Obeagu GU. The roles of Neutrophils in pregnancy. *Int. J. Curr. Res. Med. Sci*. 2023;9(5): 31-35.DOI: [10.22192/ijcrms.2023.09.05.005](https://doi.org/10.22192/ijcrms.2023.09.05.005)

Citation: Obeagu EI, Obeagu GU. Blood Transfusion Considerations in High-Risk Pregnancies: Strategies and Outcomes. *Elite Journal of Medical Sciences*, 2024; 2(5):40-50

41. Eze R, Obeagu EI, Nwakulite A, Okoroiwu IL, Vincent CC, Okafor CJ, Chukwurah EF, Chijioke UO, Amaechi CO. Evaluation of Copper Status and Some Red Cell Parameters of Pregnant Women in Enugu State, South Eastern Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(30A):67-71.
42. Obeagu EI, Obeagu GU. Molar Pregnancy: Update of prevalence and risk factors. *Int. J. Curr. Res. Med. Sci.* 2023;9(7): 25-28.DOI: [10.22192/ijcrms.2023.09.07.005](https://doi.org/10.22192/ijcrms.2023.09.07.005)
43. Obeagu EI, Bunu UO. Factors that influence unmet need for family planning. *International Journal of Current Research in Biology and Medicine*. 2023;8(1):23-27.
44. Ibebuikie JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, Nwanjo HU, Agu GC, Ezenwuba CO, Nwagu SA, Akujuobi AU. Barriers to utilization of maternal health services in southern senatorial district of Cross Rivers state, Nigeria. *International Journal of Advanced Multidisciplinary Research*. 2017;4(8): 1-9.DOI: [10.22192/ijamr.2017.04.08.001](https://doi.org/10.22192/ijamr.2017.04.08.001)
45. Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth*. 2023;6(1):203-211. <http://research.sdpublishers.net/id/eprint/2819/>.
46. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of coagulation parameters in malaria infected pregnant women in Imo state, Nigeria. *International Journal of Current Research in Medical Sciences*. 2018;4(9): 41-9.DOI: [10.22192/ijcrms.2018.04.09.006](https://doi.org/10.22192/ijcrms.2018.04.09.006)
47. Obeagu EI, Obeagu GU. Postpartum haemorrhage among women delivering through spontaneous vaginal delivery: Prevalence and risk factors. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(8): 22-6.DOI: [10.22192/ijcpcps.2023.10.08.003](https://doi.org/10.22192/ijcpcps.2023.10.08.003)
48. Obeagu E, Eze RI, Obeagu EI, Nnatuanya IN, Dara EC. ZINC LEVEL IN APPARENTLY PREGNANT WOMEN IN URBAN AREA. *Madonna University journal of Medicine and Health Sciences*. 2022;2(1):134-48. <https://www.journal.madonnauniversity.edu.ng/index.php/medicine/article/view/40>.
49. Rahman MM, Abe SK, Rahman MS, Kanda M, Narita S, Bilano V, Ota E, Gilmour S, Shibuya K. Maternal anemia and risk of adverse birth and health outcomes in low-and middle-income countries: systematic review and meta-analysis. *The American journal of clinical nutrition*. 2016;103(2):495-504.
50. Ogomaka IA, Obeagu EI. Malaria in Pregnancy Amidst Possession of Insecticide Treated Bed Nets (ITNs) in Orlu LGA of Imo State, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(41B):380-386.
51. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. SICKLE CELL ANAEMIA: A GESTATIONAL ENIGMA. *migration*. 2023; 17:18.
52. Ifeanyi OE, Uzoma OG. A review on erythropoietin in pregnancy. *J. Gynecol. Womens Health*. 2018;8(3):1-4. https://www.academia.edu/download/56538560/A_Review_on_Erythropoietin_in_Pregnancy.pdf.
53. Ifeanyi OE. A review on pregnancy and haematology. *Int. J. Curr. Res. Biol. Med.* 2018;3(5): 26-8.DOI: [10.22192/ijcrbm.2018.03.05.006](https://doi.org/10.22192/ijcrbm.2018.03.05.006)

Citation: Obeagu EI, Obeagu GU. Blood Transfusion Considerations in High-Risk Pregnancies: Strategies and Outcomes. *Elite Journal of Medical Sciences*, 2024; 2(5):40-50

54. Nwosu DC, Nwanjo HU, Obeagu EI, Ibebuike JE, Ezeama MC. Ihekireh. Changes in liver enzymes and lipid profile of pregnant women with malaria in Owerri, Nigeria. *International Journal of Current Research and Academic Review*. 2015;3(5):376-383.
55. Ibebuike JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, Nwanjo HU, Agu GC, Ezenwuba CO, Nwagu SA, Akujuobi AU. Factors that influence women's utilization of primary health care services in Calabar Cros river state, Nigeria. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2017;4(7):28-33.
56. Eze R, Ezeah GA, Obeagu EI, Omeje C, Nwakulite A. Evaluation of iron status and some haematological parameters of pregnant women in Enugu, South Eastern Nigeria. *World Journal of Pharmaceutical and Medical Research*. 2021;7(5):251-4.
57. Elemchukwu Q, Obeagu EI, Ochei KC. Prevalence of Anaemia among Pregnant Women in Braithwaite Memorial Specialist Hospital (BMSH) Port Harcourt. *IOSR Journal of Pharmacy and Biological Sciences*. 2014;9(5):59-64.
58. Akandinda M, Obeagu EI, Katonera MT. Non Governmental Organizations and Women's Health Empowerment in Uganda: A Review. *Asian Research Journal of Gynaecology and Obstetrics*. 2022;8(3):12-26.
59. Tandon R, Jain A, Malhotra P. Management of iron deficiency anemia in pregnancy in India. *Indian Journal of Hematology and Blood Transfusion*. 2018; 34:204-215.
60. Montoro M, Cucala M, Lanas Á, Villanueva C, Hervás AJ, Alcedo J, Gisbert JP, Aisa AP, Bujanda L, Calvet X, Mearin F. Indications and hemoglobin thresholds for red blood cell transfusion and iron replacement in adults with gastrointestinal bleeding: An algorithm proposed by gastroenterologists and patient blood management experts. *Frontiers in Medicine*. 2022; 9:903739.
61. Kapur D, Nath Agarwal K, Kumari Agarwal D. Nutritional anemia and its control. *The Indian Journal of Pediatrics*. 2002; 69:607-616.
62. Gamde MS, Obeagu EI. IRON DEFICIENCY ANAEMIA: ENEMICAL TO PREGNANCY. *European Journal of Biomedical*. 2023;10(9):272-275.
[links/64f63358827074313ffae7b/IRON-DEFICIENCY-ANAEMIA-ENEMICAL-TO-PREGNANCY.pdf](https://www.ejbm.com/links/64f63358827074313ffae7b/IRON-DEFICIENCY-ANAEMIA-ENEMICAL-TO-PREGNANCY.pdf).
63. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Evaluation of levels of some inflammatory cytokines in preeclamptic women in owerri. *Journal of Pharmaceutical Research International*. 2021;33(42A):53-65.
64. Hasan MM, Magalhaes RJ, Garnett SP, Fatima Y, Tariqujjaman M, Pervin S, Ahmed S, Mamun AA. Anaemia in women of reproductive age in low-and middle-income countries: progress towards the 2025 global nutrition target. *Bulletin of the World Health Organization*. 2022;100(3):196.
65. Paulman PM, Paulman A, Harrison JD, Nasir LS, Bryan SK, Collier DS. Signs and Symptoms in Family Medicine E-Book: A Literature-Based Approach. Elsevier Health Sciences; 2011.
66. Stoffel NU, von Siebenthal HK, Moretti D, Zimmermann MB. Oral iron supplementation in iron-deficient women: How much and how often? *Molecular aspects of medicine*. 2020; 75:100865.

67. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Studies of Some Haemostatic Variables in Preeclamptic Women in Owerri, Imo State, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(42B):39-48.
68. Obeagu EI, Obeagu GU. Postpartum haemorrhage among women delivering through spontaneous vaginal delivery: Prevalence and risk factors. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(8):22-26.
69. Obeagu EI, Obeagu GU. Sick Cell Anaemia in Pregnancy: A Review. *International Research in Medical and Health Sciences*. 2023;6(2):10-13.
70. Al RA, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, Haberal A. Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. *Obstetrics & Gynecology*. 2005;106(6):1335-1340.
71. Ngwenya S. Postpartum hemorrhage: incidence, risk factors, and outcomes in a low-resource setting. *International journal of women's health*. 2016:647-650.
72. Obeagu EI, Ubosi NI, Uzoma G. Maternal Hemorrhage and Blood Transfusions: Safeguarding Pregnancy Health. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):26-35.
73. Obeagu EI, Obeagu GU. The Vital Role of Blood Transfusions during Pregnancy: A Comprehensive Review. *Asian Journal of Dental and Health Sciences*. 2024;4(1):26-31.